Greencare Capital is an Investment Vehicle to identify investment opportunities in and acquisitions of companies and businesses in the rapidly changing regulatory environment surrounding legal Medicinal Cannabis as well as investment opportunities within the Hemp and CBD wellness sectors and other plant-based medicines.
Greencare Capital identifies business acquisition opportunities in new cultivation technologies, products and services related to the evolution of cannabis as an agricultural product, in Hemp and CBD wellness sectors or in other plant-based medicines.
Our vision is to provide investors the best business opportunities in the pharmaceutical field and medical use of cannabis and other plants. Driven by passion we look forward in innovation and technologies to guarantee our clients diversified range of investment tools.
As we strive to improve people’s lives and generate long-term value for our stakeholders, we are guided by these principles:
There are over 100 active compounds contained in Cannabis plants, with cannabinoids and terpenes being the two largest groups. Two cannabinoids are the most significant of these compounds:
It is the terpenes in Cannabis which are responsible for its strong smell.
In the United Kingdom THC and other cannabinoids are deemed controlled substances under the MDA 1971, while CBD is not deemed to be a controlled substance.
The Cannabis market has four distinct categories:
In addition to the Cannabis market, there is also a substantial Hemp industry which has four main product groups; fibres, shivs, pharmaceuticals and seeds.